Tag Archives: Anaptys Bio

Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More

If it seems like biotech investments have defied the financial headwinds of the pandemic, maybe it’s because they have. In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies. The figures come from the National Venture Capital Association and financial research firm Pitchbook. This week […]

Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More

During the state of the union address this year, President Trump pledged to end HIV transmission within the next decade. A key part of that plan is an HIV prevention drug made by Gilead Sciences. That drug has now become the center of a patent dispute between the Foster City, CA, drug maker and the […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged A2 Therapeutics, Abraham Scaria, Acadia Pharmaceuticals, ADHD, Aerie Pharmaceuticals, Alzheimer's disease, Anaptys Bio, Antibiotic, Arkuda Therapeutics, Ashley Winslow, AstraZeneca, atopic dermatitis, Biogen, Biotech, Biouniversa, Centers for Disease Control and Prevention, Checkmate Pharmaceuticals, China, clinical trials, CRISPR, Dauntless Pharmaceuticals, David Altarac, David Hollander, deals, Dementia, Drug Delivery, eGenesis, EIP Pharma, Eli Kalif, Entasis therapeutics, eosinophilic asthma, Epizyme, etokimab, FDA, Foundation Medicine, Galera Therapeutics, Gene editing, Gilead Sciences, Halozyme Therapeutics, HIV, Infection, Inflammation, Intrepida Bio, investing, IVERIC bio, Kleem Chaudhary, Life Sciences, MD Anderson Cancer Center in Houston, Medical Device, neflamapimod, Odylia Therapeutics, Pancreatic Cancer, Pharmakon Advisors, Ponni Subbiah, President Trump, RedHill BioPharma, Regenerative Medicine, RNA editing, Robin Isaacs, RoboticsAI, Royalty Pharma, Samsung Bioepis, Sangamo Therapeutics, Section 32, Shape Therapeutics, Shire, Stada Arzneimittel, startups, Stephen Hahn, Steve Kafka, Stryker, Sung Lee, SuperNus Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceutical, Third Rock Ventures, University of Pennsylvania, University of Texas MD Anderson Cancer Center, Vertex Pharmaceuticals | Comments Off

West Coast Bio Roundup: Illumina, CRISPR, Orexigen, Ambry & More

El Niño-driven storms returned to California this week to fill up reservoirs and snarl commutes, although we’ve got nothing to compare with what’s happening down South. A few biotech parades were rained on out West. The two rival parties battling for CRISPR patent rights tried to undermine each other’s cases, filing documents to kick off […]

Posted in National blog main, National top stories, San Diego blog main, San Diego top stories, San Francisco, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories | Tagged "Visionary Kids: Steve Jobs", Ambry Genetics, Anaptys Bio, Aspyrian Therapeutics, B cells, Berkeley, Biotech, Broad Institute of Harvard and MIT, change, Charles Dunlop, Contrave, CRISPR, El Nino, Five Prime Therapeutics, FP-1039, Francis deSou, GlaxoSmithKline, Grail, Helix, Illumina, ImmuSoft, JAMA, Jay Flatley, Joshua Sharfstein, Life Sciences, Liquid Biopsy, NuVasive, Orexigen, Rain, Tizona Therapeutics, University of California, Xoma | Comments Off

San Diego’s Biotech Leaders of Tomorrow: ‘We Are the Wildcatters’

(Xconomy contributor Juliet Preston helped pull this story together) One more sign that the U.S. life sciences industry is in upheaval became evident last month, when the Chicago real estate group Jones Lang LaSalle issued its 2012 report on life sciences clusters. The study revealed that biomedical clusters in several smaller U.S. cities are gaining […]

Posted in National blog main, National top stories, San Diego, San Diego blog main, San Diego top stories | Tagged Advanced Proteomics, Algae-based Biofuels, Anaptys Bio, Biocom, Bioinformatics, Biologics, Biomedical Diagnostics, BioNano Genomics, Biotech, cancer, Carmine Stengone of Avelas Bioscience, Cellana, Chris Hibberd, cleantech, Cypher Genomics Ashley Van Zeeland, David Nelson, David Urso, Devices, Digital Healths., Domain Ventures, Drugs, Eclipse Therapeutics, Entrepreneurship, Epic Sciences, Erik Holmlin, Financing, funding, General Atomics, Genetic Diagnostics, Genoa Pharmaceuticals, Genomics, Hamza Suria, Healthtech, Industrial Biotechnology, innovation, Jennifer Cayer, Joe Panetta, Keith Murphy, Life Sciences, Martin Sabarsky, Matt Dixon, Michael Kamdar, Michelle M. Hanna, MoneyTree Survey, Nimesh Shah, Organova, people, Peter Chu, Peter Klemm, Rempex Therapeutics, RiboMed Biotechnologies, Sapphire Energy, Scott Forrest, SkinMedica, startups, Stem Cell Therapies, Synthetic Genomics, Tech, Technology Clusters, Ted Ebel, The Scripps Research Institute, Tioga Pharmaceuticals, Todd Dickinson, Verenium, Wireless Health | Comments Off

Avalon Ventures, Coming Off Zynga Investment, Raising 10th Fund

Venture investing in the life sciences has been declining over the past year or so, along with a contraction in the number of VC firms that are actively investing. Yet San Diego’s Avalon Ventures, which also has a strong presence in Boston, seems to be running contrary to the industry’s overall trend. The venture firm—which […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, San Diego, San Diego blog main, San Diego top stories | Tagged Anaptys Bio, app, Avalon Ventures, Awarepoint, Backupify, Brady Bohrmann, Cardeas Pharma, Court Turner, deals, funding, innovation, Innovation Economy, Internet, IT, Jay Lichter, Kevin Kinsella, Kinvey, Life Sciences, Mark Pincus, MOGL, people, Rich Levandov, Software, startups, Steve Tomlin, VC, Venture Capital, Venture Fund-Raising, Web, Zynga | Comments Off